Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial

Applied Health Economics and Health Policy

Volumn 9, Issue 5, 2011, Pages 305-315

  Kattan, Michael W ^a   Earnshaw, Stephanie R ^b   McDade, Cheryl L ^b   Black, Libby K ^c   Andriole, Gerald L ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost utility; Dutasteride; Prostate cancer

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HIDDEN MARKOV MODEL; HIGH RISK POPULATION; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROTEIN BLOOD LEVEL; SIMULATION; URINE INCONTINENCE; URINE RETENTION;

AGED; ANTINEOPLASTIC AGENTS; AZASTEROIDS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 80052202345     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11592200-000000000-00000     Document Type: Article

References (33)

1. Thompson IM, Goodman PH, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 213-22
2. Andriole GL, Bostwick DG, Brawley OW, et al., for the REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
3. Earnshaw SR, McDade CL, Black LK, et al. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics 2010; 28 (6): 489-505
4. Black L, Naslund MJ, Gilbert TD, et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006; 12: S99-110
5. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Stat databases: Incidence- SEER 13 Regs public-use, November 2004 sub for expanded races (1992-2002), and incidence-SEER 13 Regs excluding AK public-use, November 2004 sub for Hispanics (1992- 2002), released April 2005 [online]. Available from URL: Http://seer.cancer.gov/canques/incidence.html [Accessed 2010 Feb 17]
6. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993; 150: 85-9 (Pubitemid 23175978)
7. Bhatnagar V, Stewart ST, Huynh V, et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 2006; 9: 136-46 (Pubitemid 43970962)
8. Red book. Vol 52.Greenwood Village (CO):Micromedex, Inc., 2009
9. Coley CM, Barry MJ, Fleming C, et al. Clinical guidelines: Early detection of prostate cancer. Part II. Ann InternMed 1997; 126 (6): 468-79 (Pubitemid 27114478)
10. American Medical Association. Current procedural terminology CPT 2001. Chicago (IL): AMA Press, 2008
11. Ingenix, Inc. The essential RBRVS: A comprehensive listing of RBRVS values for CPT and HCPCS codes. New York: St. Anthony Publishing, 2008
12. Commisson on Cancer. National Cancer Data Base. Benchmark reports (v2.0) [online]. Available from URL: Http://cromwell.facs.org/BMarks/BMPub/Ver10/DxRx/ BMPub-DxRx.cfm [Accessed 2010 Feb 17]
13. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28 (7): 1117-23
14. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010; 126: 2387-93
15. Albertsen PC, Lowe FC, Roehrborn CG. Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study. Clin Ther 1999; 21 (6): 1006-24 (Pubitemid 29326160)
16. US Department of Labor, US Bureau of Labor Statistics. US city average, not seasonally adjusted medical care [online]. Available from URL: Http://data.bls.gov/PDQ/out side.jsp?survey=cu [Accessed 2010 Feb 16]
17. Hanks GE, Dunlap K. A comparison of the cost of various treatment methods for early cancer of the prostate. Int J Radiat Oncol Biol Phys 1986; 12 (10): 1879-81 (Pubitemid 17182232)
18. Litwin MS, Smith RB, Thind A, et al. Cost-efficient radical prostatectomy with a clinical care path. J Urol 1996; 155 (3): 989-93 (Pubitemid 26052695)
19. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002; 20 (12): 2869-75 (Pubitemid 34651516)
20. Benoit RM, Cohen JK, Miller Jr RJ. Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology 1998; 52 (5): 820-4 (Pubitemid 28489709)
21. Koch MO, Smith Jr JA, Hodge EM, et al. Prospective development of a cost-efficient program for radical retropubic prostatectomy. Urology 1994; 44 (3): 311-8 (Pubitemid 24273811)
22. Silverstein AD, Weizer AZ, Dowell JM, et al. Cost comparison of radical retropubic and radical perineal prostatectomy: Single institution experience. Urology 2004; 63 (4): 746-50 (Pubitemid 38479422)
23. Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CaPSURE database. Urology 2001; 57: 499-503 (Pubitemid 32192981)
24. Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Managed Care Pharm 2002; 8 (5): 343-52
25. National Vital Statistics. Reports. Deaths: Final data for 2005. Table 5: number of deaths and death rates by age, and age-adjusted death rates by specified Hispanic origin, race for non-Hispanic population, and sex: United States, 2005. Natl Vital Stat Rep 2005; 56 (10): 23
26. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community dwelling population. Pharmacoeconomics 1999; 15 (4): 369-76 (Pubitemid 29190028)
27. Brenmer KE, Chong C, Tomlinson G. A review and metaanalysis of prostate cancer utilities. Med Decis Making 2007; 27: 288-98 (Pubitemid 46801746)
28. Ackerman SJ, Rein AL, Blute M, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: Part I. Methods. Urology 2000; 56: 972-80
29. Weinstein MC. From cost-effectiveness ratios to resource allocation: Where to draw the line. In: Sloan FA, editor. Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995
30. Eichler H, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28 (Pubitemid 39390832)
31. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20: 332-42 (Pubitemid 30479101)
32. Hefland BT, Evans RM, McVary KT. Medical treatment of LUTS/BPH: Analysis of 8.7 million American men [abstract]. J Urol 2009; 181 (4 Suppl.): 647
33. Hershman D, Sundararajan V, Jacobson JS, et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis. J Clin Oncol. 2002; 20 (1): 9-16 (Pubitemid 34032590)